DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

Phase 3

Recruiting

Conditions: Migraine

Interventions: Drug: Placebo-Matching Ubrogepant
Drug: Ubrogepant

First Posted Date: 2021-11-18

Last Posted Date: 2025-05-15

Lead Sponsor: AbbVie

Target Recruit Count: 1059

Registration Number: NCT05125302

Locations: 🇺🇸
Paradigm Clinical Research - San Diego /ID# 269608, San Diego, California, United States
🇺🇸
MCB Clinical Research Centers /ID# 231625, Colorado Springs, Colorado, United States
🇺🇸
New England Institute for Clinical Research /ID# 230635, Stamford, Connecticut, United States

and more 108 locations

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Phase 2

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia (CLL)
Small Lymphocytic Lymphoma (SLL)

Interventions: Drug: Venetoclax
Drug: Obinutuzumab
Drug: Ibrutinib

First Posted Date: 2021-11-03

Last Posted Date: 2024-06-18

Lead Sponsor: AbbVie

Target Recruit Count: 20

Registration Number: NCT05105841

Locations: 🇯🇵
National Cancer Center Hospital /ID# 232449, Chuo-ku, Tokyo, Japan
🇯🇵
University Hospital Kyoto Prefectural University of Medicine /ID# 239883, Kyoto-shi, Kyoto, Japan
🇯🇵
Tohoku University Hospital /ID# 238433, Sendai-shi, Miyagi, Japan

and more 17 locations

Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's Disease

Phase 1

Completed

Conditions: Parkinson's Disease

Interventions: Drug: ABBV-951

First Posted Date: 2021-10-26

Last Posted Date: 2023-03-24

Lead Sponsor: AbbVie

Target Recruit Count: 16

Registration Number: NCT05094050

Locations: 🇺🇸
Texas Movement Disorder Specialists /ID# 238607, Georgetown, Texas, United States
🇺🇸
The Movement Disorder Clinic of Oklahoma /ID# 238610, Tulsa, Oklahoma, United States
🇺🇸
Carolina Phase 1, LLC /ID# 239836, Raleigh, North Carolina, United States

and more 7 locations

A Study to Assess Disease Activity in Adult Participants With Axial Spondyloarthritis Who Receive Upadacitinib in a Real-world Setting

Recruiting

Conditions: Axial Spondylarthritis (r-axSpA)

Interventions: Drug: Upadacitinib

First Posted Date: 2021-10-26

Last Posted Date: 2025-05-06

Lead Sponsor: AbbVie

Target Recruit Count: 352

Registration Number: NCT05094128

Locations: 🇩🇪
Rheumatologie Kassel /ID# 275998, Kassel, Niedersachsen, Germany
🇩🇪
Rheumatologische Facharztpraxis /ID# 240477, Naumburg (Saale), Germany
🇩🇪
Aurich & Sieburg, Magdeburg /ID# 240518, Magdeburg, Sachsen-Anhalt, Germany

and more 68 locations

A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis

Active, not recruiting

Conditions: Atopic Dermatitis

First Posted Date: 2021-10-18

Last Posted Date: 2024-09-30

Lead Sponsor: AbbVie

Target Recruit Count: 873

Registration Number: NCT05081557

Locations: 🇷🇺
National Research Center Institute of Immunology of the FMBA of Russia /ID# 245221, Moscow, Moskva, Russian Federation
🇷🇺
LLC Medical Center ABC of Health /ID# 244816, Kazan, Tatarstan, Respublika, Russian Federation
🇦🇷
Hospital Universitario Austral /ID# 241607, Pilar, Buenos Aires, Argentina

and more 137 locations

Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon

Phase 4

Completed

Conditions: Cystic Fibrosis
Chronic Pancreatitis

Interventions: Drug: CREON

First Posted Date: 2021-10-06

Last Posted Date: 2024-07-23

Lead Sponsor: AbbVie

Target Recruit Count: 30

Registration Number: NCT05069597

Locations: 🇺🇸
Valley Children's Hospital /ID# 231452, Madera, California, United States
🇺🇸
Cleveland Clinic Main Campus /ID# 245864, Cleveland, Ohio, United States
🇺🇸
Asr, Llc /Id# 239566, Nampa, Idaho, United States

and more 18 locations

A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease

Phase 2

Terminated

Conditions: Crohn's Disease

Interventions: Drug: ABBV-154
Drug: Placebo

First Posted Date: 2021-10-05

Last Posted Date: 2024-10-03

Lead Sponsor: AbbVie

Target Recruit Count: 176

Registration Number: NCT05068284

Locations: 🇺🇸
Southern California Res. Ctr. /ID# 233512, Coronado, California, United States
🇺🇸
Hoag Memorial Hosp Presbyterian /ID# 233555, Irvine, California, United States
🇺🇸
University of Colorado Hospital /ID# 239361, Aurora, Colorado, United States

and more 163 locations

A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis

Phase 2

Terminated

Conditions: Psoriasis

Interventions: Drug: Placebo
Drug: Cedirogant

First Posted Date: 2021-09-14

Last Posted Date: 2023-11-29

Lead Sponsor: AbbVie

Target Recruit Count: 156

Registration Number: NCT05044234

Locations: 🇺🇸
West Virginia Research /ID# 238517, Morgantown, West Virginia, United States
🇺🇸
Lenus Research & Medical Group /ID# 238695, Sweetwater, Florida, United States
🇯🇵
Mie University Hospital /ID# 239275, Tsu-shi, Mie, Japan

and more 50 locations

Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO)

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Peritoneal Cancer

Interventions: Drug: Mirvetuximab soravtansine

First Posted Date: 2021-09-13

Last Posted Date: 2024-12-20

Lead Sponsor: AbbVie

Target Recruit Count: 79

Registration Number: NCT05041257

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
The University of Alabama at Birmingham - Division of Gynecology Oncology O'Neal Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
Alaska Women's Cancer Care/Providence Alaska Medical Center, Anchorage, Alaska, United States

and more 75 locations

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

Phase 1

Active, not recruiting

Conditions: Colorectal Cancer
Advanced Solid Tumors
Non-Small Cell Lung Cancer
Gastroesophageal Adenocarcinoma

Interventions: Drug: ABBV-400
Drug: Trifluridine/Tipiracil
Drug: Bevacizumab

First Posted Date: 2021-09-01

Last Posted Date: 2025-02-20

Lead Sponsor: AbbVie

Target Recruit Count: 520

Registration Number: NCT05029882

Locations: 🇫🇷
Centre Georges François Leclerc /ID# 244450, Dijon, France
🇫🇷
AP-HP - Hopital Européen Georges Pompidou /ID# 250481, Paris, France
🇮🇱
Rambam Health Care Campus /ID# 231218, Haifa, H_efa, Israel

and more 79 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy